<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130565">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402284</url>
  </required_header>
  <id_info>
    <org_study_id>110221</org_study_id>
    <secondary_id>11-C-0221</secondary_id>
    <nct_id>NCT01402284</nct_id>
  </id_info>
  <brief_title>Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients</brief_title>
  <official_title>Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Carfilzomib is an experimental anti-cancer drug that has not yet been approved for
      treating multiple myeloma. Lenalidomide is a drug that may stop tumor growth and help the
      immune system kill cancer cells. Dexamethasone is a drug that helps stop inflammation. It is
      sometimes used to treat (alone or with other drugs) certain types of cancer, especially
      multiple myeloma. This combination of drugs has not been tested in people with multiple
      myeloma. Researchers want to see whether it is safe and effective for this group.

      Objectives:

      - To test the effectiveness of combined carfilzomib, lenalidomide, and dexamethasone in
      treating multiple myeloma.

      Eligibility:

      - People at least 18 years of age who have multiple myeloma that has not been treated.

      Design:

        -  Participants will be screened with a medical history and physical exam. They will also
           have blood and urine tests, a bone marrow sample, and molecular imaging studies.

        -  Participants will have eight 28-day cycles of treatment. The combined study drugs will
           be given as tablets and injections. Those in the study will be monitored with frequent
           blood tests, bone marrow samples, and molecular imaging studies. In addition to current
           standard measures to determine clinical responses, molecular tests will be conducted to
           define evidence of minimal residual disease.

        -  After the first four cycles of therapy, those who are eligible for a stem cell
           transplant will have stem cells collected and stored for use if the cancer returns.

        -  After stem cell collection, participants will have the second four treatment cycles.

           -, If the disease has improved or is stable at the end of eight cycles, those in the
           study may have another 12 cycles of low-dose (maintenance) lenalidomide alone.

        -  Participants will have regular follow-up visits after the end of the study
           chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Multiple myeloma (MM) is an incurable plasma cell neoplasm with a median survival of
           3-4 years.

        -  Novel agent combinations with proteasome inhibitors demonstrate improved response rates
           while increasing survival in MM patients.

        -  A common debilitating side effect of the proteasome inhibitor bortezomib is neuropathy.

        -  Carfilzomib is a new proteasome inhibitor with potent anti-MM effects and decreased
           peripheral neuropathy

      Objectives:

      -Evaluate toxicity, including peripheral neuropathy, of carfilzomib, lenalidomide, and
      dexamethasone (CRd) in untreated MM patients

      Eligibility:

        -  Newly diagnosed patients with histologically confirmed multiple myeloma

        -  Age greater than or equal to 18 years

        -  Creatinine Clearance (CrCl) greater than or equal to 60 ml/min. CrCl will be calculated
           using the Cockcroft- Gault method. If the calculated CrCl based on Cockcroft-Gault
           method is &lt;60 mL/min, patient will have a 24 hr urine collection to measure CrCl. The
           measured CrCl must also be greater than or equal to 60 ml/min.

        -  Without serious co-morbidity that would interfere with receipt of CRd

        -  Absolute neutrophil count (ANC) greater than or equal to 1.0 K/uL, hemoglobin greater
           than or equal to 8 g/dL, and platelet count greater than or equal to 75 K/uL

        -  Adequate hepatic function, with bilirubin less than 1.5 x the ULN, and AST and ALT less
           than 3.0 x ULN

      Design:

        -  Single arm, single stage phase II trial of combination therapy (carfilzomib,
           lenalidomide, and dexamethasone) for untreated multiple myeloma patients with an early
           stopping rule for toxicity

        -  Patients will receive 8 cycles of induction combination therapy of CRd

        -  Each cycle consists of 28-days

        -  After 4 cycles of therapy, transplant eligible patients will undergo stem cell
           collection

        -  Patients achieving stable disease or better after 8 cycles of CRd will receive
           lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will
           have the option to continue extended dosing (phase II) for one additional year.

        -  Patients will have routine blood work with SPEP and free light chains monthly

        -  Pre- and post-treatment bone marrow biopsies will be obtained for confirmation of
           diagnosis and correlative studies

        -  Patients will also undergo evaluation for minimal residual disease at regular interval
           time points, using multi-parametric flow cytometry and FDG PET-CT

        -  A single stage phase II design will be employed, with an early stopping rule. Unless 4
           or more patients in the first 20 have Grade 3 or higher neurologic toxicity in the
           first 2 completed cycles, a total of 45 evaluable patients will be enrolled in this
           study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 21, 2011</start_date>
  <completion_date type="Anticipated">September 1, 2026</completion_date>
  <primary_completion_date type="Actual">July 10, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate toxicity</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 8 cycles of induction combination therapy of CRd. Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 8 cycles of combination CRd, patients may continue Lenalidomide for 12 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Cycle 1: 20 mg/m2 IV infusion over 30 minutes on days 1 and 2, then 36 mg/m2 IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m2 IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination CRd, patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>After 8 cycles of combination CRd, patients may continue Lenalidomide for 12 cycles</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Newly diagnosed patients with histologically confirmed MM based on the following
             criteria:

               1. Clonal plasma cells in the bone marrow

               2. Measurable disease within the past 4 weeks defined by any one of the following:

                    1. Serum monoclonal protein greater than or equal to 1.0 g/dL

                    2. Urine monoclonal protein greater than200 mg/24 hour

                    3. Serum immunoglobulin free light chain greater than 10 mg/dL AND abnormal
                       kappa/lambda ratio

               3. Evidence of underlying end organ damage attributed to underlying plasma cell
                  proliferative disorder meeting at least one of the following:

                    1. Hypercalcemia: serum calcium greater than or equal to 2.65 mmol/L

                    2. Renal Insufficiency: serum creatinine greater than 2.0 mg/dL

                    3. Anemia: hemoglobin value less than10 g/dL or 2 g/dL less than normal
                       reference

                    4. Bone disease: lytic lesions, severe osteopenia or pathological fractures

          -  Creatinine Clearance greater than or equal to 60 ml/min. CrCl will be calculated by
             Cockcroft-Gault method. CrCl (calculated) = (140 Age) x Mass (in kilograms) x [0.85
             if Female] 72 times Serum Creatinine (in mg/dL). If calculated CrCl based on
             Cockcroft-Gault method is &lt;60 mL/min, patient will have a 24 hr urine collection to
             measure CrCl. The measured CrCl msut be also greater than or equal to 60 ml/min.

          -  Age greater than or equal to 18 years. Because no dosing or adverse event data are
             currently available on the use of carfilzomib in combination with lenalidomide in
             patients less than18 years of age, children are excluded from this study, but will be
             eligible for future pediatric trials.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Absolute neutrophil count (ANC) greater than or equal to 1.0 K/uL, hemoglobin greater
             than or equal to 8 g/dL (transfusions are permissible), and platelet count greater
             than or equal to 75 K/uL

          -  Adequate hepatic function, with bilirubin less than 1.5 times the ULN, and AST and
             ALT less than 3.0 times ULN.

          -  All study participants must be able to tolerate one of the following
             thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin
             (coumadin).

          -  All study participants must be registered into the mandatory RevAssist program, and
             be willing and able to comply with the requirements of RevAssist .

          -  Females of childbearing potential (FCBP) must have a negative serum or urine
             pregnancy test within 10 14 days and again within 24 hours prior to prescribing
             lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either
             commit to continued abstinence from heterosexual intercourse or begin TWO acceptable
             methods of birth control, one highly effective method and one additional effective
             method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP
             must also agree to ongoing pregnancy testing. Men must agree to use a latex condom
             during sexual contact with a FCBP even if they have had a successful vasectomy.

          -  Subjects must be able to give informed consent

        EXCLUSION CRITERIA:

          -  Prior or concurrent systemic treatment for MM.

               -  Treatment of hypercalcemia or spinal cord compression or aggressively
                  progressing myeloma with corticosteroids is permitted.

               -  Bisphosphonates are permitted.

               -  Treatment with corticosteroids for indications other than MM is permitted.

               -  Radiotherapy is permitted.

               -  Treatment for smoldering myeloma is permitted.

          -  Plasma cell leukemia

          -  Pregnant or lactating females. Because there is a potential risk for adverse events
             in nursing infants secondary to treatment of the mother with carfilzomib in
             combination with lenalidomide, breastfeeding should be discontinued if the mother is
             treated with carfilzomib and lenalidomide. These potential risks may also apply to
             other agents used in this study.

          -  Uncontrolled hypertension or diabetes

          -  Active hepatitis B or C infection

          -  Has significant cardiovascular disease with NYHA Class III or IV symptoms, or
             hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction
             within 3 months prior to enrollment, or unstable angina, or unstable arrhythmia as
             determined by history and physical examination. Echocardiogram will be performed if
             clinically warranted.

          -  Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel
             disease, or bowel resection that would prevent absorption

          -  Uncontrolled intercurrent illness including but not limited to active infection or
             psychiatric illness/social situations that would compromise compliance with study
             requirements

          -  Significant neuropathy greater than or equal to Grade 3 at baseline

          -  Contraindication to any concomitant medication, including antivirals, anticoagulation
             prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy

          -  Major surgery within 1 month prior to enrollment

          -  Recruitment Strategies:

               -  Patients that progress from the SMM and MGUS Natural History Study (NCI
                  Protocol: 10-C-0096) will be potential candidates.

               -  Other participant sources will be from outside physician referrals.

               -  Our ongoing natural history study and outside physician referral network has a
                  high representation of minorities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Roschewski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0221.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>International Myeloma Working Group.. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun;121(5):749-57.</citation>
    <PMID>12780789</PMID>
  </reference>
  <reference>
    <citation>Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bj√∂rkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007 May 20;25(15):1993-9. Epub 2007 Apr 9.</citation>
    <PMID>17420512</PMID>
  </reference>
  <reference>
    <citation>Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516-20. Epub 2007 Nov 1.</citation>
    <PMID>17975015</PMID>
  </reference>
  <verification_date>January 13, 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>July 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Novel Drug Combinations</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Decreased Peripheral Neuropathy</keyword>
  <keyword>Auto Stem Cell Transplant</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
